Fig. 1: LINC00858 is highly expressed in colon cancer and silencing of LINC00858 inhibits proliferation, migration, and invasion of colon cancer cells.

A LINC00858 expression in colon cancer determined in-silico using GEPIA. Red boxes represent CC samples, and the gray boxes represent normal samples. B Expression of LINC00858 in cancer tissues and normal adjacent tissues of patients with colon cancer (n = 50) quantified by RT-qPCR, *p < 0.05 vs. normal adjacent tissues. C LINC00858 expression in human normal colon cell line (NCM460) and colon cancer cell lines (HCT166, SW480, Caco2 and SW620) quantified by RT-qPCR. *p < 0.05 vs. *p < 0.01 vs. NCM460 cell line. D The expression of LINC00858 in SW480 and HCT166 cells quantified by RT-qPCR. E CCK-8 assay for measuring the viability of SW480 and HCT166 cells in each group. F EdU staining to determine the proliferation of SW480 and HCT166 cells in each group. G TUNEL staining to detect the apoptosis of SW480 and HCT166 cells in each group. H Western blot assay to detect the expression of apoptosis related proteins cleaved caspase-3/total Caspase 3 and cleaved PARP/total PARP in SW480 and HCT166 cells from each group. I Transwell assay to assess the migration and invasion abilities of SW480 and HCT166 cells in each group. *p < 0.05. Statistical comparisons between adjacent tissues and cancer tissues were conducted using paired t test and other two group data were compared using unpaired t test. Data from multiple groups were compared using one-way ANOV with Tukey’s post hoc tests. Repeated measures ANOVA with Bonferroni’s post hoc test was used to compare data obtained at different time points,. All cell experiments were repeated three times.